Global Angina Pectoris Drugs Market Size study, by Type (Stable Angina, Unstable Angina), by Drug Class (Beta Blockers, Anticoagulants), by Distribution Channel, and Regional Forecasts 2022-2032

The Global Angina Pectoris Drugs Market is valued at approximately USD 11.37 billion in 2023 and is projected to grow steadily at a compound annual growth rate (CAGR) of 4.00% over the forecast period from 2024 to 2032. Angina pectoris, a symptomatic manifestation of myocardial ischemia, continues to be a pressing cardiovascular concern, particularly among aging populations and individuals with chronic lifestyle disorders. With healthcare systems worldwide intensifying their focus on reducing cardiovascular morbidity and mortality, pharmacological interventions for angina are receiving renewed attention. The market is witnessing a clinical shift from traditional monotherapy to combination regimens that leverage synergistic effects of anti-anginal agents such as beta blockers, calcium channel blockers, and newer anticoagulants. This progression is underpinned by an increase in guideline-directed medical therapy and heightened physician awareness surrounding risk stratification and patient-specific treatment algorithms.

The steady rise in the prevalence of coronary artery disease, sedentary lifestyles, tobacco consumption, and diabetes is fuelling demand for angina therapeutics across both high-income and emerging economies. In tandem, improvements in clinical infrastructure and diagnostic capabilities have enhanced the early detection of stable and unstable angina forms, ensuring timely therapeutic intervention. Leading pharmaceutical giants are investing substantially in the development of novel drug classes that not only manage symptoms but also improve long-term cardiovascular outcomes. Moreover, the integration of digital health platforms and remote monitoring solutions is enabling better medication adherence, further strengthening market potential. However, despite robust progress, cost-intensive branded therapies and adverse drug interactions in polypharmacy scenarios remain significant hurdles—especially in low- and middle-income countries.

Technological advancements and strategic collaborations among pharmaceutical companies are creating new avenues for drug innovation and distribution. Biosimilars and generic formulations of commonly prescribed agents like beta blockers and anticoagulants are expanding market access by offering affordable options to underserved patient groups. At the same time, the emergence of data-driven clinical decision-making is refining prescription behaviors, reducing instances of therapeutic redundancy, and optimizing patient outcomes. Regulatory bodies are also playing a pivotal role by expediting drug approvals and updating treatment guidelines to reflect evidence-based innovations, thereby fostering a more agile and patient-centric treatment landscape.

Regionally, North America leads the global angina drugs market, propelled by a sophisticated healthcare system, high disease burden, and early adoption of advanced treatment protocols. The U.S. continues to dominate with robust R&D activities, frequent product launches, and favorable reimbursement frameworks. Europe trails closely, benefitting from increased public health expenditure and a strong emphasis on preventive cardiovascular care. Meanwhile, Asia Pacific is expected to grow at the fastest pace due to rising healthcare investments, a surging elderly population, and growing cardiovascular health awareness in countries like China, India, and Japan. Latin America and the Middle East & Africa, though still developing markets, are demonstrating promise through evolving regulatory frameworks and international pharmaceutical collaborations.

Major market player included in this report are:
• AstraZeneca PLC
• Bayer AG
• Pfizer Inc.
• Novartis AG
• Sanofi
• Merck & Co., Inc.
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company

The detailed segments and sub-segment of the market are explained below:

By Type
• Stable Angina
• Unstable Angina

By Drug Class
• Beta Blockers
• Anticoagulants

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.